Skip to main content
Stonvex
Loading…
Home
Activity
Screener
Portfolio
Community
Stonvex publishes market data and research only.
Not investment advice. Not a registered investment advisor.
Read disclaimer
.
Stonvex
Search…
⌘K
Search…
⌘K
Log in
Get Started
← Back to rankings
ALNY
Live
Save
Overview
Financials
Filings
Earnings Calls
Short Interest
Ownership
Ratings
Peers
News
Loading latest news…
52w low +17.5%
A
ALNY
Alnylam Pharmaceuticals, Inc.
Stonvex
☁️ News word cloud
Top words across the last 50 articles for this ticker.
alnylam
market
drug
pharmaceuticals
billion
growth
biotech
significant
expected
disease
treatment
pipeline
strong
therapeutics
2025
study
potential
results
research
nyse
StonvexStonvexStonvexStonvex